Skip to main content

Table 1 Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates

From: Erratum to: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

   International units relative to factor IX   
Brand name Manufacturer Factor II Factor VII Factor IX Factor X Viral inactivation Additional information
Bebulin VH Baxter BioScience, Austria 120 (13) 100 100 Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar Heparin added
Beriplex P/N CSL Behring, Germany 128 68 100 152 Pasteurisation at 60°C for 10 hours, and nanofiltration Protein C; antithrombin, heparin and albumin added
Cofact Sanquin, the Netherlands 56-140 28-80 100 56-140 Solvent/detergent and 15 nm nanofiltration Antithrombin added
KASKADIL LFB, France 148 40 100 160 Solvent/detergent Heparin added
Octaplex Octapharma, Austria and France 44-152 36-96 100 50 Solvent/detergent and nanofiltration Heparin added; low activated factor VII content
Profilnine SD Grifols, USA 148 (11) 100 64 Solvent/detergent -
Prothrombinex VF CSL Bioplasma, Australia 100 (-) 100 100 Dry heat, 80°C for 72 hours and nanofiltration Antithrombin and heparin added
Prothromplex T Baxter BioScience, Austria 100 85 100 100 Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar Antithrombin and heparin added
UMAN Complex D.I. Kedrion, Italy 100 (-) 100 80 Solvent/detergent and dry heat, 100°C for 30 minutes Antithrombin and heparin added
  1. Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. Factor VII presented in parentheses for three-factor PCCs.